Rational Use of Intensity-Modulated Radiation Therapy: The Importance of Clinical Outcome

Seminars in Radiation Oncology

Volumn 22, Issue 1, 2012, Pages 40-49

  De Neve, Wilfried ^a   De Gersem, Werner ^a   Madani, Indira ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CLINICAL ASSESSMENT; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENDPOINT DETERMINATION; EVIDENCE-BASED MEDICINE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RISK ASSESSMENT;

EID: 83455259678     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2011.09.003     Document Type: Review

References (47)

1. Brahme A., Roos J.E., Lax I. Solution of an integral equation encountered in rotation therapy. Phys Med Biol 1982, 27:1221-1229.
2. Lax I., Brahme A. Rotation therapy using a novel high-gradient filter. Radiology 1982, 145:473-478.
3. Eklöf A., Ahnesjö A., Brahme A. Photon beam energy deposition kernels for inverse radiotherapy planning. Acta Oncol 1990, 29:447-454.
4. Carol M., Grant W.H., Pavord D., et al. Initial clinical experience with the Peacock intensity modulation of a 3-D conformal radiation therapy system. Stereotact Funct Neurosurg 1996, 66:30-34.
5. Glatstein E. Intensity-modulated radiation therapy: The inverse, the converse, and the perverse. Semin Radiat Oncol 2002, 12:272-281.
6. Veldeman L., Madani I., Hulstaert F., et al. Evidence behind use of intensity-modulated radiotherapy: A systematic review of comparative clinical studies. Lancet Oncol 2008, 9:367-375.
7. Pow E.H., Kwong D.L., McMillan A.S., et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006, 66:981-991.
8. Pignol J., Olivotto I., Rakovitch E. Phase III randomized study of intensity modulated radiation therapy versus standard wedging technique for adjuvant breast radiotherapy. Int J Radiat Oncol Biol Phys 2006, 66(suppl 1):S1.
9. Donovan E., Bleakley N., Denholm E., et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 2007, 82:254-264. Breast Technology Group.
10. Nutting C.M., Morden J.P., Harrington K.J., et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicentre randomised controlled trial. Lancet Oncol 2011, 12:127-136. PARSPORT trial management group.
11. Kam M.K., Leung S.F., Zee B., et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007, 25:4873-4879.
12. Pignol J.P., Olivotto I., Rakovitch E., et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 2008, 26:2085-2092.
13. Barnett G.C., Wilkinson J.S., Moody A.M. Randomized controlled trial of forward-planned intensity-modulated radiotherapy for early breast cancer: Interim results at 2 years. Int J Radiat Oncol Biol Phys 2011 Feb 22, [Epub ahead of print].
14. Livi L., Buonamici F.B., Simontacchi G., et al. Accelerated partial breast irradiation with IMRT: New technical approach and interim analysis of acute toxicity in a phase III randomized clinical trial. Int J Radiat Oncol Biol Phys 2010, 77:509-515.
15. Chen A.M., Li B.Q., Farwell D.G., et al. Improved dosimetric and clinical outcomes with intensity-modulated radiotherapy for head-and-neck cancer of unknown primary origin. Int J Radiat Oncol Biol Phys 2011, 79:756-762.
16. Clavel S., Nguyen D.H., Fortin B. Simultaneous integrated boost using intensity-modulated radiotherapy compared with conventional radiotherapy in patients treated with concurrent carboplatin and 5-fluorouracil for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2011 Feb 1, [Epub ahead of print].
17. Hsin C.H., Chen T.H., Young Y.H., et al. Comparison of otologic complications between intensity-modulated and two-dimensional radiotherapies in nasopharyngeal carcinoma patients. Otolaryngol Head Neck Surg 2010, 143:662-668.
18. Vergeer M.R., Doornaert P.A., Rietveld D.H., et al. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: Results of a nonrandomized prospective study using a standardized follow-up program. Int J Radiat Oncol Biol Phys 2009, 74:1-8.
19. Givens D.J., Karnell L.H., Gupta A.K., et al. Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2009, 135:1209-1217.
20. Laskar S., Bahl G., Muckaden M., et al. Nasopharyngeal carcinoma in children: Comparison of conventional and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008, 72:728-736.
21. Madani I., Vakaet L., Bonte K., et al. Intensity-modulated radiotherapy for cervical lymph node metastases from unknown primary cancer. Int J Radiat Oncol Biol Phys 2008, 71:1158-1166.
22. Fang F.M., Chien C.Y., Tsai W.L., et al. Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy-a longitudinal study. Int J Radiat Oncol Biol Phys 2008, 72:356-364.
23. Dijkema T., Terhaard C.H., Roesink J.M., et al. Large cohort dose-volume response analysis of parotid gland function after radiotherapy: Intensity-modulated versus conventional radiotherapy. Int J Radiat Oncol Biol Phys 2008, 72:1101-1109.
24. van Rij C.M., Oughlane-Heemsbergen W.D., Ackerstaff A.H. Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life. Radiol Oncol 2008, 3:41.
25. Yao M., Karnell L.H., Funk G.F., et al. Health-related quality-of-life outcomes following IMRT versus conventional radiotherapy for oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2007, 69:1354-1360.
26. Freedman G.M., Li T., Nicolaou N., et al. Breast intensity-modulated radiation therapy reduces time spent with acute dermatitis for women of all breast sizes during radiation. Int J Radiat Oncol Biol Phys 2009, 74:689-694.
27. Morganti A.G., Cilla S., Valentini V., et al. Phase I-II studies on accelerated IMRT in breast carcinoma: Technical comparison and acute toxicity in 332 patients. Radiother Oncol 2009, 90:86-92.
28. McDonald M.W., Godette K.D., Butker E.K., et al. Long-term outcomes of IMRT for breast cancer: A single-institution cohort analysis. Int J Radiat Oncol Biol Phys 2008, 72:1031-1040.
29. Dolezel M., Odrazka K., Vaculikova M., et al. Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: Direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy. Strahlenther Onkol 2010, 186:197-202.
30. Sharma N.K., Li T., Chen D.Y., et al. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011, 80:437-444.
31. Odrazka K., Dolezel M., Vanasek J., et al. Late toxicity after conformal and intensity-modulated radiation therapy for prostate cancer: Impact of previous surgery for benign prostatic hyperplasia. Int J Urol 2010, 17:784-790.
32. Al-Mamgani A., Heemsbergen W.D., Peeters S.T., et al. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2009, 73:685-691.
33. Alongi F., Fiorino C., Cozzarini C., et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol 2009, 93:207-212.
34. Matzinger O., Duclos F., van den Bergh A., et al. Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991. Eur J Cancer 2009, 45:2825-2834. EORTC Radiation Oncology Group.
35. Namiki S., Ishidoya S., Ito A. Five-year follow-up of health-related quality of life after intensity-modulated radiation therapy for prostate cancer. Jpn J Clin Oncol 2009, 39:732-738.
36. Zelefsky M.J., Levin E.J., Hunt M., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:1124-1129.
37. Liao Z.X., Komaki R.R., Thames H.D. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:775-781.
38. Kidd E.A., Siegel B.A., Dehdashti F., et al. Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2010, 77:1085-1091.
39. Bazan J.G., Hara W., Hsu A., et al. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer 2011, 117:3342-3351.
40. Saarilahti K., Arponen P., Vaalavirta L., et al. The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol 2008, 87:383-390.
41. Jain N., Krull K.R., Brouwers P., et al. Neuropsychological outcome following intensity-modulated radiation therapy for pediatric medulloblastoma. Pediatr Blood Cancer 2008, 51:275-279.
42. Mohan R., Wu Q., Manning M., et al. Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. Int J Radiat Oncol Biol Phys 2000, 46:619-630.
43. Thorwarth D., Eschmann S.M., Paulsen F., et al. Hypoxia dose painting by numbers: A planning study. Int J Radiat Oncol Biol Phys 2007, 68:291-300.
44. Duprez F., De Neve W., De Gersem W., et al. Adaptive dose painting by numbers for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011, 80:1045-1055.
45. Ling C.C., Humm J., Larson S., et al. Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000, 47:551-560.
46. Bentzen S.M. Theragnostic imaging for radiation oncology: Dose-painting by numbers. Lancet Oncol 2005, 6:112-117.
47. Galvin J.M., De Neve W. Intensity modulating and other radiation therapy devices for dose painting. J Clin Oncol 2007, 25:924-930.